Condition: Metastatic HER2 Negative Breast Carcinoma · Brain Metastases · Capecitabine · Sponsor: Hunan Cancer Hospital
This study is a single-arm, multicenter, open-labeled clinical study of UTD1 combined with Capecitabine in metastatic HER2-negative breast cancaner patients with brain metastases. This study aims to evaluate the efficacy and safety of UDT1 combined with capecitabine in metastatic HER2-negative breast cancer patients with brain metastases.
This description comes directly from the study's public registry record.
Quchang Ouyang · +8673189762161 · oyqc1969@126.com
Always discuss trial participation with your own doctor first.
| Quchang Ouyang | Changsha, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05535413